uniQure N.V. (NASDAQ:QURE – Get Free Report)’s stock price gapped down before the market opened on Monday after Barclays downgraded the stock from an overweight rating to an equal weight rating. The stock had previously closed at $23.46, but opened at $22.28. Barclays now has a $28.00 price target on the stock, down from their previous price target of $60.00. uniQure shares last traded at $22.63, with a volume of 497,326 shares trading hands.
QURE has been the subject of a number of other reports. Leerink Partners boosted their target price on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. William Blair upgraded shares of uniQure to a “strong-buy” rating in a research note on Wednesday, September 23rd. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a report on Wednesday, June 17th. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research report on Wednesday, July 29th. Finally, The Goldman Sachs Group reduced their price objective on uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.73.
Check Out Our Latest Research Report on QURE
Hedge Funds Weigh In On uniQure
uniQure Trading Up 1.1%
The company has a 50 day moving average of $42.72 and a 200 day moving average of $33.56. The firm has a market cap of $1.60 billion, a P/E ratio of -5.75 and a beta of 1.06. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01.
uniQure (NASDAQ:QURE – Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The business had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same period in the previous year, the company earned ($0.69) earnings per share. Analysts predict that uniQure N.V. will post -3.82 EPS for the current fiscal year.
About uniQure
uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.
uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.
See Also
- Five stocks we like better than uniQure
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
